Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 13/20 | 0.50 |
| ▸ | BRD4 | O60885 | 13/20 | 0.50 |
| ▸ | BRDT | Q58F21 | 11/20 | 0.50 |
| ▸ | VRK1 | Q99986 | 3/20 | 0.47 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.47 |
| ▸ | PARP1 | P09874 | 2/20 | 0.46 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.45 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13360849 | 0.87 | BRD4 (0.49) | PLK1BRD4BRDTVRK1RPS6KA3 | |
| SCHEMBL12956561 | 0.86 | RPS6KA3 (0.62) | PLK1BRD4BRDTVRK1RPS6KA3 | |
| SCHEMBL13104998 | 0.80 | BRD4 (0.72) | PLK1BRD4BRDTRPS6KA3PARP1 | |
| SCHEMBL13104981 | 0.77 | RPS6KA3 (0.49) | PLK1BRD4BRDTVRK1RPS6KA3 | |
| SCHEMBL12956560 | 0.76 | PLK1 (0.69) | PLK1BRD4BRDTRPS6KA3PLK3 | |
| SCHEMBL21527053 | 0.75 | RPS6KA3 (0.62) | PLK1BRD4BRDTVRK1RPS6KA3 | |
| SCHEMBL862198 | 0.75 | RPS6KA3 (0.62) | PLK1BRD4BRDTVRK1RPS6KA3 | |
| SCHEMBL13104992 | 0.74 | PLK1 (0.76) | PLK1BRD4BRDTRPS6KA3PLK3 | |
| SCHEMBL12957059 | 0.72 | BRD4 (0.44) | PLK1BRD4BRDT | |
| SCHEMBL862111 | 0.71 | PLK1 (0.77) | PLK1BRD4BRDTRPS6KA3PLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194818-A1 | Antiproliferative agents; polo-like kinase inhibitors | GRAUERT MATTHIAS | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194818-A1 | Antiproliferative agents; polo-like kinase inhibitors | CCNK, CDK1, PLK1 | PLK1 3/4885BRD4 2309/4885BRDT 1291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.